PMC:7228307 / 55650-56614
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1147 | 612-619 | Gene | denotes | FcγRIIb | Gene:2213 |
| 1148 | 564-567 | Gene | denotes | BCR | Gene:613 |
| 1149 | 9-27 | Disease | denotes | IgE mAb omalizumab | MESH:D007589 |
| 1150 | 73-91 | Disease | denotes | allergic disorders | MESH:D004342 |
| 1151 | 834-841 | Disease | denotes | allergy | MESH:D004342 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T424 | 9-12 | Body_part | denotes | IgE | http://purl.org/sig/ont/fma/fma62875 |
| T425 | 296-299 | Body_part | denotes | IgE | http://purl.org/sig/ont/fma/fma62875 |
| T426 | 348-356 | Body_part | denotes | basophil | http://purl.org/sig/ont/fma/fma62862 |
| T427 | 361-370 | Body_part | denotes | mast cell | http://purl.org/sig/ont/fma/fma66784 |
| T428 | 366-370 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
| T429 | 485-488 | Body_part | denotes | IgE | http://purl.org/sig/ont/fma/fma62875 |
| T430 | 510-514 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
| T431 | 515-518 | Body_part | denotes | IgE | http://purl.org/sig/ont/fma/fma62875 |
| T432 | 560-563 | Body_part | denotes | IgE | http://purl.org/sig/ont/fma/fma62875 |
| T433 | 577-589 | Body_part | denotes | cell surface | http://purl.org/sig/ont/fma/fma67653 |
| T434 | 577-581 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
| T435 | 701-704 | Body_part | denotes | IgE | http://purl.org/sig/ont/fma/fma62875 |
| T436 | 719-722 | Body_part | denotes | IgE | http://purl.org/sig/ont/fma/fma62875 |
| T437 | 726-731 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
| T438 | 773-776 | Body_part | denotes | IgE | http://purl.org/sig/ont/fma/fma62875 |
| T439 | 864-867 | Body_part | denotes | IgE | http://purl.org/sig/ont/fma/fma62875 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T108 | 73-81 | Disease | denotes | allergic | http://purl.obolibrary.org/obo/MONDO_0004980 |
| T109 | 834-841 | Disease | denotes | allergy | http://purl.obolibrary.org/obo/MONDO_0005271 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T942 | 101-102 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
| T943 | 115-117 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
| T944 | 176-183 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
| T945 | 331-333 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
| T946 | 366-370 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T947 | 371-381 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activation |
| T948 | 387-390 | http://purl.obolibrary.org/obo/CLO_0053001 | denotes | 114 |
| T949 | 508-514 | http://purl.obolibrary.org/obo/CL_0000236 | denotes | B‐cell |
| T950 | 575-581 | http://purl.obolibrary.org/obo/CL_0000236 | denotes | B‐cell |
| T951 | 612-614 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
| T952 | 646-648 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
| T953 | 724-731 | http://purl.obolibrary.org/obo/CL_0000236 | denotes | B cells |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T38 | 334-336 | Chemical | denotes | RI | http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753 |
LitCovid-sample-PD-IDO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T239 | 82-91 | http://purl.obolibrary.org/obo/OGMS_0000045 | denotes | disorders |
| T240 | 366-370 | http://purl.obolibrary.org/obo/CL_0000000 | denotes | cell |
| T241 | 510-514 | http://purl.obolibrary.org/obo/CL_0000000 | denotes | cell |
| T242 | 519-529 | http://purl.obolibrary.org/obo/IDO_0000607 | denotes | production |
| T243 | 577-581 | http://purl.obolibrary.org/obo/CL_0000000 | denotes | cell |
| T244 | 705-715 | http://purl.obolibrary.org/obo/IDO_0000607 | denotes | production |
| T245 | 726-731 | http://purl.obolibrary.org/obo/CL_0000000 | denotes | cells |
LitCovid-sample-Pubtator
| Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
|---|---|---|---|---|---|
| 1147 | 612-619 | Gene | denotes | FcγRIIb | Gene:2213 |
| 1148 | 564-567 | Gene | denotes | BCR | Gene:613 |
| 1149 | 9-27 | Disease | denotes | IgE mAb omalizumab | MESH:D007589 |
| 1150 | 73-91 | Disease | denotes | allergic disorders | MESH:D004342 |
| 1151 | 834-841 | Disease | denotes | allergy | MESH:D004342 |
LitCovid-sample-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T314 | 0-964 | Sentence | denotes | The anti‐IgE mAb omalizumab is an IgG1 mAb approved for the treatment of allergic disorders.110, 111 A similar but Fc‐engineered IgG1 mAb XmAb7195, currently in early clinical testing, contains the affinity‐enhancing SELF modifications.112 Both mAbs sterically neutralize the interaction between IgE and its high‐affinity receptor FcεRI to prevent basophil and mast cell activation.113, 114 However, XmAb7195 exhibited more efficient removal (sweeping; discussed later) of circulating IgE and also inhibited B‐cell IgE production, presumably by binding to the IgE BCR on the B‐cell surface and coclustering with FcγRIIb via its affinity‐enhanced Fc domain.112 Thus, XmAb7195’s selective modulation of IgE production by IgE+ B cells in addition to its enhanced clearance of IgE may offer significantly improved therapeutic benefits in allergy therapy beyond simple IgE neutralization.112 The “SELF” mutations have also been used in agonistic mAbs (discussed later). |
LitCovid-sample-UniProt
| Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
|---|---|---|---|---|---|
| T735 | 361-365 | Protein | denotes | mast | https://www.uniprot.org/uniprot/Q9NL57|https://www.uniprot.org/uniprot/Q9NBD7|https://www.uniprot.org/uniprot/A4V279 |
LitCovid-sample-PD-FMA
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T423 | 9-12 | Body_part | denotes | IgE | http://purl.org/sig/ont/fma/fma62875 |
| T424 | 296-299 | Body_part | denotes | IgE | http://purl.org/sig/ont/fma/fma62875 |
| T425 | 348-356 | Body_part | denotes | basophil | http://purl.org/sig/ont/fma/fma62862 |
| T426 | 361-370 | Body_part | denotes | mast cell | http://purl.org/sig/ont/fma/fma66784 |
| T427 | 366-370 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
| T428 | 485-488 | Body_part | denotes | IgE | http://purl.org/sig/ont/fma/fma62875 |
| T429 | 510-514 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
| T430 | 515-518 | Body_part | denotes | IgE | http://purl.org/sig/ont/fma/fma62875 |
| T431 | 560-563 | Body_part | denotes | IgE | http://purl.org/sig/ont/fma/fma62875 |
| T432 | 577-589 | Body_part | denotes | cell surface | http://purl.org/sig/ont/fma/fma67653 |
| T433 | 577-581 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
| T434 | 701-704 | Body_part | denotes | IgE | http://purl.org/sig/ont/fma/fma62875 |
| T435 | 719-722 | Body_part | denotes | IgE | http://purl.org/sig/ont/fma/fma62875 |
| T436 | 726-731 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
| T437 | 773-776 | Body_part | denotes | IgE | http://purl.org/sig/ont/fma/fma62875 |
| T438 | 864-867 | Body_part | denotes | IgE | http://purl.org/sig/ont/fma/fma62875 |
LitCovid-sample-PD-MAT
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T23 | 463-468 | http://purl.obolibrary.org/obo/MAT_0000488 | denotes | later |
| T24 | 957-962 | http://purl.obolibrary.org/obo/MAT_0000488 | denotes | later |
LitCovid-sample-PD-GO-BP-0
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T130 | 361-381 | http://purl.obolibrary.org/obo/GO_0045576 | denotes | mast cell activation |
| T131 | 366-381 | http://purl.obolibrary.org/obo/GO_0001775 | denotes | cell activation |
LitCovid-sample-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T46 | 73-81 | Disease | denotes | allergic | http://purl.obolibrary.org/obo/MONDO_0004980 |
| T47 | 834-841 | Disease | denotes | allergy | http://purl.obolibrary.org/obo/MONDO_0005271 |
LitCovid-sample-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T42 | 834-841 | Phenotype | denotes | allergy | http://purl.obolibrary.org/obo/HP_0012393 |
LitCovid-sample-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T130 | 361-381 | http://purl.obolibrary.org/obo/GO_0045576 | denotes | mast cell activation |
| T131 | 366-381 | http://purl.obolibrary.org/obo/GO_0001775 | denotes | cell activation |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T130 | 361-381 | http://purl.obolibrary.org/obo/GO_0045576 | denotes | mast cell activation |
| T131 | 366-381 | http://purl.obolibrary.org/obo/GO_0001775 | denotes | cell activation |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T314 | 0-964 | Sentence | denotes | The anti‐IgE mAb omalizumab is an IgG1 mAb approved for the treatment of allergic disorders.110, 111 A similar but Fc‐engineered IgG1 mAb XmAb7195, currently in early clinical testing, contains the affinity‐enhancing SELF modifications.112 Both mAbs sterically neutralize the interaction between IgE and its high‐affinity receptor FcεRI to prevent basophil and mast cell activation.113, 114 However, XmAb7195 exhibited more efficient removal (sweeping; discussed later) of circulating IgE and also inhibited B‐cell IgE production, presumably by binding to the IgE BCR on the B‐cell surface and coclustering with FcγRIIb via its affinity‐enhanced Fc domain.112 Thus, XmAb7195’s selective modulation of IgE production by IgE+ B cells in addition to its enhanced clearance of IgE may offer significantly improved therapeutic benefits in allergy therapy beyond simple IgE neutralization.112 The “SELF” mutations have also been used in agonistic mAbs (discussed later). |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T42 | 834-841 | Phenotype | denotes | allergy | http://purl.obolibrary.org/obo/HP_0012393 |